These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 19533748)

  • 21. CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis.
    Fletcher JM; Lonergan R; Costelloe L; Kinsella K; Moran B; O'Farrelly C; Tubridy N; Mills KH
    J Immunol; 2009 Dec; 183(11):7602-10. PubMed ID: 19917691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative analyses of regulatory T cell subsets in patients with hepatocellular carcinoma: a crucial role of CD25(-) FOXP3(-) T cells.
    Kakita N; Kanto T; Itose I; Kuroda S; Inoue M; Matsubara T; Higashitani K; Miyazaki M; Sakakibara M; Hiramatsu N; Takehara T; Kasahara A; Hayashi N
    Int J Cancer; 2012 Dec; 131(11):2573-83. PubMed ID: 22419479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in peripheral blood level of regulatory T cells in patients with malignant melanoma during treatment with dendritic cell vaccination and low-dose IL-2.
    Bjoern J; Brimnes MK; Andersen MH; Thor Straten P; Svane IM
    Scand J Immunol; 2011 Mar; 73(3):222-33. PubMed ID: 21204893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer.
    Rozková D; Tiserová H; Fucíková J; Last'ovicka J; Podrazil M; Ulcová H; Budínský V; Prausová J; Linke Z; Minárik I; Sedivá A; Spísek R; Bartůnková J
    Clin Immunol; 2009 Apr; 131(1):1-10. PubMed ID: 19201656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human leukocyte antigen-G and regulatory T cells during specific immunotherapy for pollen allergy.
    Sørensen AE; Johnsen CR; Dalgaard LT; Würtzen PA; Kristensen B; Larsen MH; Ullum H; Søes-Petersen U; Hviid TV
    Int Arch Allergy Immunol; 2013; 162(3):237-52. PubMed ID: 24022071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phenotype alterations in regulatory T-cell subsets in primary HIV infection and identification of Tr1-like cells as the main interleukin 10-producing CD4+ T cells.
    Chevalier MF; Didier C; Petitjean G; Karmochkine M; Girard PM; Barré-Sinoussi F; Scott-Algara D; Weiss L
    J Infect Dis; 2015 Mar; 211(5):769-79. PubMed ID: 25281758
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increase of circulating CD4+CD25highFoxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2.
    Berntsen A; Brimnes MK; thor Straten P; Svane IM
    J Immunother; 2010 May; 33(4):425-34. PubMed ID: 20386464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increase in activated Treg in TIL in lung cancer and in vitro depletion of Treg by ADCC using an antihuman CCR4 mAb (KM2760).
    Kurose K; Ohue Y; Sato E; Yamauchi A; Eikawa S; Isobe M; Nishio Y; Uenaka A; Oka M; Nakayama E
    J Thorac Oncol; 2015 Jan; 10(1):74-83. PubMed ID: 25325779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of transplantation tolerance by allogeneic donor-derived CD4(+)CD25(+)Foxp3(+) regulatory T cells.
    Velásquez-Lopera MM; Eaton VL; Lerret NM; Correa LA; Decresce RP; García LF; Jaramillo A
    Transpl Immunol; 2008 May; 19(2):127-35. PubMed ID: 18503888
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells.
    François V; Ottaviani S; Renkvist N; Stockis J; Schuler G; Thielemans K; Colau D; Marchand M; Boon T; Lucas S; van der Bruggen P
    Cancer Res; 2009 May; 69(10):4335-45. PubMed ID: 19435913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical implication of peripheral CD4+CD25+ regulatory T cells and Th17 cells in myasthenia gravis patients.
    Masuda M; Matsumoto M; Tanaka S; Nakajima K; Yamada N; Ido N; Ohtsuka T; Nishida M; Hirano T; Utsumi H
    J Neuroimmunol; 2010 Aug; 225(1-2):123-31. PubMed ID: 20472307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer.
    Flammiger A; Weisbach L; Huland H; Tennstedt P; Simon R; Minner S; Bokemeyer C; Sauter G; Schlomm T; Trepel M
    Eur J Cancer; 2013 Apr; 49(6):1273-9. PubMed ID: 23266046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased prevalence of interleukin-17-producing CD4(+) tumor infiltrating lymphocytes in human oral squamous cell carcinoma.
    Lee JJ; Chang YL; Lai WL; Ko JY; Kuo MY; Chiang CP; Azuma M; Chen CW; Chia JS
    Head Neck; 2011 Sep; 33(9):1301-8. PubMed ID: 21837700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer.
    Kottke T; Sanchez-Perez L; Diaz RM; Thompson J; Chong H; Harrington K; Calderwood SK; Pulido J; Georgopoulos N; Selby P; Melcher A; Vile R
    Cancer Res; 2007 Dec; 67(24):11970-9. PubMed ID: 18089828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deficient CD4+CD25+ T regulatory cell function in patients with abdominal aortic aneurysms.
    Yin M; Zhang J; Wang Y; Wang S; Böckler D; Duan Z; Xin S
    Arterioscler Thromb Vasc Biol; 2010 Sep; 30(9):1825-31. PubMed ID: 20448211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transient depletion of CD4(+) T cells augments IL-21-based immunotherapy of disseminated neuroblastoma in syngeneic mice.
    Croce M; Corrias MV; Orengo AM; Brizzolara A; Carlini B; Borghi M; Rigo V; Pistoia V; Ferrini S
    Int J Cancer; 2010 Sep; 127(5):1141-50. PubMed ID: 20039320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study.
    Pandha HS; John RJ; Hutchinson J; James N; Whelan M; Corbishley C; Dalgleish AG
    BJU Int; 2004 Aug; 94(3):412-8. PubMed ID: 15291878
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate cancer immunotherapy: the role for sipuleucel-T and other immunologic approaches.
    Arlen PM
    Oncology (Williston Park); 2011 Mar; 25(3):261-2. PubMed ID: 21548469
    [No Abstract]   [Full Text] [Related]  

  • 39. Numerical and functional assessment of blood dendritic cells in prostate cancer patients.
    Wilkinson R; Kassianos AJ; Swindle P; Hart DN; Radford KJ
    Prostate; 2006 Feb; 66(2):180-92. PubMed ID: 16173035
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients.
    Miller AM; Lundberg K; Ozenci V; Banham AH; Hellström M; Egevad L; Pisa P
    J Immunol; 2006 Nov; 177(10):7398-405. PubMed ID: 17082659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.